Less efficient g2-m checkpoint is associated with an increased risk of lung cancer in African Americans.

Cell cycle checkpoints play critical roles in the maintenance of genomic integrity. The inactivation of checkpoint genes by genetic and epigenetic mechanisms is frequent in all cancer types, as a less-efficient cell cycle control can lead to genetic instability and tumorigenesis. In an on-going case-control study consisting of 216 patients with non-small cell lung cancer, 226 population-based controls, and 114 hospital-based controls, we investigated the relationship of gamma-radiation-induced G2-M arrest and lung cancer risk. Peripheral blood lymphocytes were cultured for 90 hours, exposed to 1.0 Gy gamma-radiation, and harvested at 3 hours after gamma-radiation treatment. gamma-Radiation-induced G2-M arrest was measured as the percentage of mitotic cells in untreated cultures minus the percentage of mitotic cells in gamma-radiation-treated cultures from the same subject. The mean percentage of gamma-radiation-induced G2-M arrest was significantly lower in cases than in population controls (1.18 versus 1.44, P < 0.01) and hospital controls (1.18 versus 1.40, P = 0.01). When dichotomized at the 50th percentile value in combined controls (population and hospital controls), a lower level of gamma-radiation-induced G2-M arrest was associated with an increased risk of lung cancer among African Americans after adjusting for baseline mitotic index, age, gender, and pack-years of smoking [adjusted odd ratio (OR), 2.25; 95% confidence interval (95% CI), 0.97-5.20]. A significant trend of an increased risk of lung cancer with a decreased level of G2-M arrest was observed (P(trend) = 0.02) among African Americans, with a lowest-versus-highest quartile adjusted OR of 3.74 (95% CI, 0.98-14.3). This trend was most apparent among African American females (P(trend) < 0.01), with a lowest-versus-highest quartile adjusted OR of 11.75 (95% CI, 1.47-94.04). The results suggest that a less-efficient DNA damage-induced G2-M checkpoint is associated with an increased risk of lung cancer among African Americans. Interestingly, we observed a stronger association of DNA damage-induced G2-M arrest and lung cancer among African Americans when compared with Caucasians. If replicated, these results may provide clues to the exceedingly high lung cancer incidence experienced by African Americans.

[1]  W. Weber,et al.  Populations and genetic polymorphisms. , 1999, Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology.

[2]  C. Harris,et al.  Bleomycin-induced chromosome breaks as a risk marker for lung cancer: a case-control study with population and hospital controls. , 2003, Carcinogenesis.

[3]  J. Piette,et al.  Implication of the G2 checkpoint in the maintenance of genome integrity. , 2000, Pathologie-biologie.

[4]  M. Spitz,et al.  Mutagen sensitivity as a biological marker of lung cancer risk in African Americans. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[5]  S. Garte.  The role of ethnicity in cancer susceptibility gene polymorphisms: the example of CYP1A1. , 1998, Carcinogenesis.

[6]  R Doll,et al.  Mortality from smoking worldwide. , 1996, British medical bulletin.

[7]  R. Parshad,et al.  Chromosomal radiosensitivity during the G2 cell-cycle period of skin fibroblasts from individuals with familial cancer. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Kastan,et al.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[9]  A. Antoccia,et al.  Chromosomal sensitivity to clastogenic agents and cell cycle perturbations in Nijmegen breakage syndrome lymphoblastoid cell lines. , 1997, International journal of radiation biology.

[10]  D. Currie,et al.  Racial differences in restriction fragment length polymorphisms and messenger RNA inducibility of the human CYP1A1 gene. , 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[11]  T. Waldmann,et al.  Enhanced chromatid damage in blood lymphocytes after G2 phase x irradiation, a marker of the ataxia-telangiectasia gene. , 1990, Journal of the National Cancer Institute.

[12]  D. Johnston,et al.  Sensitivity to genotoxic effects of bleomycin in humans: Possible relationship to environmental carcinogenesis , 1989, International journal of cancer.

[13]  M. Spitz,et al.  Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. , 2000, Journal of the National Cancer Institute.

[14]  J. Little,et al.  Effects of X-irradiation on cell-cycle progression, induction of chromosomal aberrations and cell killing in ataxia telangiectasia (AT) fibroblasts. , 1985, Mutation research.

[15]  C. Harris,et al.  Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[16]  K. Kinzler,et al.  14-3-3σ Is a p53-Regulated Inhibitor of G2/M Progression , 1997 .

[17]  Thomas Ried,et al.  DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation , 2000, Nature.

[18]  E. Biros,et al.  Germ line polymorphisms of the tumor suppressor gene p53 and lung cancer. , 2001, Lung cancer.

[19]  L. Hartwell,et al.  Checkpoints: controls that ensure the order of cell cycle events. , 1989, Science.

[20]  P. May,et al.  Cell cycle control and cancer. , 2000, Pathologie-biologie.

[21]  B. Green,et al.  Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. , 2000, Pharmacogenetics.

[22]  M. Spitz,et al.  Ethnic differences in poly(ADP-ribose) polymerase pseudogene genotype distribution and association with lung cancer risk. , 1999, Carcinogenesis.

[23]  K. Isselbacher,et al.  Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. , 1999, Science.

[24]  Kathleen R. Cho,et al.  Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Spitz,et al.  Mutagen sensitivity in patients with head and neck cancers: a biologic marker for risk of multiple primary malignancies. , 1990, Journal of the National Cancer Institute.

[26]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[27]  S. Jackson,et al.  DNA-dependent protein kinase and related proteins. , 1999, Biochemical Society symposium.

[28]  E J Duell,et al.  Polymorphisms in the DNA repair gene XRCC1 and breast cancer. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[29]  H. Taubert,et al.  G2/M checkpoint is p53-dependent and independent after irradiation in five human sarcoma cell lines. , 1999, Anticancer research.

[30]  E. Biros,et al.  Polymorphism of the p53 gene within the codon 72 in lung cancer patients. , 2001, Neoplasma.

[31]  R. Parshad,et al.  X‐ray‐induced chromatid damage in relation to dna repair and cancer incidence in family members , 1993, International journal of cancer.

[32]  M. Spitz,et al.  Mutagen sensitivity exhibits a dose-response relationship in case-control studies. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[33]  Eddie Reed,et al.  CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer , 2004, Molecular Cancer.

[34]  Carl W. Miller,et al.  Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors , 2002, Genes, chromosomes & cancer.

[35]  C. Harris,et al.  Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  M. Spitz,et al.  p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. , 2002, Journal of the National Cancer Institute.

[37]  Bo Xu,et al.  Phosphorylation of serine 1387 in Brca1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation. , 2002, Cancer research.

[38]  M. Molinari.  Cell cycle checkpoints and their inactivation in human cancer , 2000, Cell proliferation.

[39]  T. Pechacek,et al.  Smoking-attributable cancer mortality in 1991: is lung cancer now the leading cause of death among smokers in the United States? , 1991, Journal of the National Cancer Institute.

[40]  Minetta C. Liu,et al.  P53 gene mutations: case study of a clinical marker for solid tumors. , 2002, Seminars in oncology.

[41]  K. Kinzler,et al.  14-3-3sigma is a p53-regulated inhibitor of G2/M progression. , 1997, Molecular cell.

[42]  P. Jeggo,et al.  Nbs1 promotes ATM dependent phosphorylation events including those required for G1/S arrest , 2002, Oncogene.

[43]  A. Taylor,et al.  Increased radiosensitivity and the basic defect in ataxia telangiectasia. , 1989, International journal of radiation biology.

[44]  M. Spitz,et al.  Cell cycle checkpoints, DNA damage/repair, and lung cancer risk. , 2005, Cancer research.

[45]  M. Lux,et al.  Population Frequencies of Single Nucleotide Polymorphisms (SNPs) in Immuno-Modulatory Genes , 2003, Human Heredity.

[46]  Thea D. Tlsty,et al.  Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 , 1992, Cell.

[47]  Alan D. Lopez,et al.  Mortality from tobacco in developed countries: indirect estimation from national vital statistics , 1992, The Lancet.

[48]  C. Canman,et al.  The role of ATM in DNA damage responses and cancer , 1998, Oncogene.

[49]  Y. Shiloh,et al.  ATM: A mediator of multiple responses to genotoxic stress , 1999, Oncogene.

[50]  Kai Rothkamm,et al.  A Double-Strand Break Repair Defect in ATM-Deficient Cells Contributes to Radiosensitivity , 2004, Cancer Research.

[51]  Amanda G Paulovich,et al.  When Checkpoints Fail , 1997, Cell.

[52]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[53]  N. Roodi,et al.  Breast cancer and CYPIA1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. , 1998, Cancer research.

[54]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.